drug pricing

The Readout Elaine Chen

Eli Lilly’s Alzheimer’s candidate, Bob Langer’s new startup, and other biotech news you need to know

The Readout Meghana Keshavan

The biotech news you missed from the weekend

The Readout Meghana Keshavan

STAT Plus: Vanda Pharmaceuticals has another suitor

The Readout Elaine Chen

Novavax will be able to supply Covid-19 vaccines this fall

The Readout Jason Mast

STAT Plus: Testing begins for a new form of PrEP

The Readout Elaine Chen

STAT Plus: Operation Warp Speed but for rare disease

The Readout Meghana Keshavan

STAT Plus: Can AstraZeneca make good on its promise?

The Readout Meghana Keshavan

STAT Plus: The surprising outperformance of a new drug against existing competitors, and other biotech updates

The Readout Elaine Chen

STAT Plus: Biohaven’s autoimmune drug disappoints, and other biotech news updates from the week

The Readout Elaine Chen

STAT Plus: Wegovy linked to lower risk of alcohol use disorder in real-world study

The Readout Meghana Keshavan

STAT Plus: Biotech’s most interesting fundraisings from the last week

The Readout Meghana Keshavan

STAT Plus: More tumult at BIO amid the company’s fourth CEO in four years

The Readout Elaine Chen

STAT Plus: In light of H5N1 outbreak, U.S. in talks with mRNA vaccine makers on bird flu

The Readout Elaine Chen

STAT Plus: Maryland takes first steps to cap drug costs

The Readout Elaine Chen

STAT Plus: Lilly doubles down on radiopharma

The Readout Meghana Keshavan

STAT Plus: The biotech news you need to read this morning

The Readout Meghana Keshavan

AstraZeneca antibody reduced Covid-19 risk in immunocompromised

The Readout Elaine Chen

STAT Plus: Blackstone wants in on red-hot immunology market

The Readout Elaine Chen

STAT Plus: Leqembi gets closer to being offered as an injection

First Opinion Robin Feldman

Cutting-edge insulin is good. But it’s the ‘trailing edge’ of older versions that can keep it affordable

The Readout Elaine Chen

Is Novavax a new meme stock?

The Readout Meghana Keshavan

STAT Plus: We now know Tome’s gene editing target

The Readout Meghana Keshavan

STAT Plus: The public wants Medicare to cover obesity drugs

The Readout Elaine Chen

STAT Plus: Yet another big financing round in immunology

The Readout Elaine Chen

STAT Plus: Pharma has over $500B in capital for deals

The Readout Elaine Chen

STAT Plus: Vertex starts gene therapy Casgevy in five patients 

First Opinion Jason Shafrin, Louis Garrison, and Melanie D. Whittington

The world is relying on the United States to get value-based drug pricing right

The Readout Meghana Keshavan

STAT Plus: Merck may have a competition for ever-scarce BCG

The Readout Meghana Keshavan

STAT Plus: ICER casts doubt on Sarepta’s DMD gene therapy